Search - tctmd.com

Displaying 1 - 20 of 60

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Biggest News of 2025

Michael O'Riordan

January 01, 2026

News Opinion CV Team Dispatch

December 2025 Dispatch for the CV Team

L.A. McKeown

December 23, 2025

News Daily News

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

L.A. McKeown

September 22, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Opinion Editor's Corner ESC 2025

What’s Going to Be Hot at ESC Congress 2025?

Michael O'Riordan

August 25, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

ACC/AHA Release New Comprehensive ACS Guidelines

Todd Neale

February 27, 2025

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

News Opinion Editor's Corner

The Biggest News of 2023: TCTMD’s Top 10

Shelley Wood

January 01, 2024

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Daily News

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

Todd Neale

September 19, 2023

News Daily News

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

L.A. McKeown

July 11, 2023

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2023

Caitlin E. Cox

February 01, 2023

News Daily News

PCSK9 Inhibition Shows Promise for Severe COVID-19 in Pilot Trial

Todd Neale

January 18, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

Advertisement

TCTMD’s Biggest News of 2025

December 2025 Dispatch for the CV Team

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

Evolocumab Gains Expanded Indication for Primary Prevention

What’s Going to Be Hot at ESC Congress 2025?

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

ACC/AHA Release New Comprehensive ACS Guidelines

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

The Biggest News of 2023: TCTMD’s Top 10

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

LDL Control Remains Poor in CAD Patients: NHANES

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

TCTMD’s Top 10 Most Popular Stories for January 2023

PCSK9 Inhibition Shows Promise for Severe COVID-19 in Pilot Trial

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content